Nasdaq
$17.52▼ 0.98%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.85BShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 9.23After-hours26.09.24 05:138-KKey event#●●●#●●●
Sarepta Therapeutics, Inc.Bullish
Sarepta Therapeutics entered into a settlement agreement on September 23, 2026, to resolve pending patent infringement litigations with REGENXBIO and the University of Pennsylvania. Under the agreement, Sarepta will pay a lump sum of $39 million within ten days and receives a release from future patent infringement claims related to its AAVrh74-based gene therapy products, including ELEVIDYS.…more
$17.52-0.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.9Overnight26.09.09 09:054Ownership
Sarepta Therapeutics, Inc.
Sarepta Therapeutics executive Ryan Ho-Yan Wong reported a change in beneficial ownership of company securities effective September 4, 2026. This filing serves as a Form 4 statement regarding the insider's stock holdings.…more
$17.52-0.98%vs prev closeView filingShare - 9.9Overnight26.09.09 09:034Ownership
Sarepta Therapeutics, Inc.
Ian Michael Estepan, an executive at Sarepta Therapeutics, reported a change in his beneficial ownership of company stock as of September 4, 2026. This filing is a standard Form 4 report detailing the insider's transaction.…more
$17.52-0.98%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 21:34#●●●#●●●
Sarepta Reports SRP-1003 Reduced Disease-Causing RNA in Preclinical Study…more
Sarepta Therapeutics announced that its SRP-1003 candidate reduced disease-causing RNA by up to 80% in a preclinical model of myotonic dystrophy. This remains an early-stage finding that requires further clinical validation.…more
$17.52-0.98%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.30Pre-market26.09.30 21:38
●●●●●●●● ●●●●● ●●●●●●
Sarepta Therapeutics presented new data demonstrating the clinically meaningful functional benefits of ELEVIDYS in ambulatory patients aged 8 to 12. These findings expand the evidence base for the treatment's efficacy across a broader age range of Duchenne muscular dystrophy patients.…more
$17.52-0.98%vs prev closeShareBenzinga - 9.8Regular26.09.09 02:47
●●●●●●●● ●●●●● ●●●●●●
Sarepta Therapeutics stock fell after Novartis reported that its Phase 3 trial for a myotonic dystrophy treatment failed to meet primary endpoints. The market reacted negatively to the news, impacting Sarepta, which is also developing a therapy for the same condition.…more
$17.52-0.98%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report